This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
There is a new way for investors to bet on cannabis - the AdvisorShares Poseidon Dynamic Cannabis ETF targets about 20 of the biggest names in U.S. cannabis. It comes at a time when it's still difficult for investors to access the space. Cheddar News cannabis reporter Chloe Aiello spoke with co-founder and managing director for Poseidon Investment Management, Emily Paxhia.
Joellen Russell, Professor at the University of Arizona, joins Cheddar Climate to discuss how poor academic curricula and misinformation online are hindering efforts to educate children about climate change, as well as how Science Moms is providing resources to moms to help create a safer world for their children.
Another successful spaceflight is in the books for Jeff Bezos' Blue Origin. The company's third human spaceflight blasted off from Van Horn, TX. on Saturday, lasting about ten minutes from takeoff to landing. The crew, which included former NFL star and current GMA host Michael Strahan, traveled to the edge of space and experienced a few minutes of weightlessness before the capsule descended back to earth. Andrew Chanin, CEO of ProcureAM, joined Cheddar's Opening Bell to discuss the significance of the launch.
The U.S. Government is making its first major move toward encouraging nuclear energy in the U.S., as it pushes toward a sustainable future. Scott Waldman, White House reporter for Politico's E&E News joined Cheddar News to break down the developments. "There's definitely an audience for this now since we're looking at the value of nuclear in terms of climate policy," he said, regarding the prospects for bipartisan support.
Google reportedly has announced that its employees must declare their vaccination status by January 18 or face a loss of pay, administrative leave, and eventual termination.
Carlo and Baker cover the latest data showing the Omicron wave has likely started, Pfizer's Covid pill, Jan. 6 and a box office rescue attempt courtesy of Spider-Man.
Upward Farms is an indoor vertical farming company on a mission to heal our broken food system and reconnect consumers with organic locally-grown food. The Brooklyn-based company uses its controlled environment farms to grow organic leafy greens, which are sold at whole foods markets in New York City. Upward Farms co-founder and CEO Jason Green joined Cheddar Climate to discuss.
One of the biggest hurdles when it comes to widespread electric vehicle adoption is consumer hesitation about their ability to keep their EV charged if they take a longer trip outside of their locality. Now, electric companies nationwide are teaming up as part of a coalition to build out a network of EV charging stations spanning major U.S. travel corridors. Kellen Schefter, director of electric transportation at the Edison Electric Institute, joins Cheddar Climate to discuss the coalition's plans, how drivers can compare fueling up with gas to recharging an EV on a long trip, how the charging network will be funded, and more.
As more states begin to legalize recreational marijuana, there's a growing interest in legalizing cannabis cultivation. As the rise in cannabis farms expands across the U.S., more research is being done to examine its impact on the planet. Michael Katz, executive director at Mendocino Cannabis Alliance, joins Cheddar News to talk about the carbon footprint of cannabis farms.
